Introduction: The Transformative Power of Targeted Research Funding

Type 1 diabetes (T1D) remains one of the most challenging autoimmune conditions of our time. Affecting roughly 1.45 million people in the United States alone and millions more worldwide, T1D demands lifelong management and carries significant health risks, including diabetic ketoacidosis, cardiovascular disease, and neuropathy. Understanding the genetic underpinnings of T1D is not an academic luxury — it is a critical pathway toward prevention, early intervention, and ultimately a cure. While many organizations contribute to T1D research, the Juvenile Diabetes Research Foundation (JDRF) stands apart as the single largest charitable funder of T1D research globally. Its unwavering commitment to genetic research has reshaped the scientific landscape, accelerating discoveries that would otherwise have proceeded at a glacial pace. Without sustained JDRF funding, the progress we have made in unravelling the genetic code of T1D could have taken decades longer to achieve.

The Legacy of JDRF: A History of Commitment to Genetic Research

Founded in 1970 by parents of children with Type 1 diabetes, JDRF began as a grassroots organization dedicated to finding a cure. Over five decades, it has evolved into a global powerhouse of diabetes research funding, having invested more than $2.5 billion into research across all facets of the disease. From its earliest days, JDRF recognized that T1D is fundamentally a genetic disease — not in the sense of simple inheritance, but as a complex interplay between multiple susceptibility genes and environmental triggers. That early recognition was pivotal. While other funding agencies viewed T1D primarily through a metabolic or immunological lens, JDRF made the strategic decision to invest heavily in the nascent field of human genetics. That decision paid dividends. The foundation funded the first large-scale genome-wide association studies (GWAS) for T1D, supported the creation of biobanks of DNA samples from families with multiple affected members, and underwrote the computational infrastructure needed to analyze the staggering volume of data those studies produced. Today, JDRF continues to fund the next generation of genetic research, from single-cell sequencing to CRISPR-based gene editing.

Decoding the Genetic Architecture of Type 1 Diabetes

The Central Role of the HLA Region

The most significant genetic contributors to T1D risk reside within the human leukocyte antigen (HLA) region on chromosome 6. This stretch of DNA encodes proteins that are essential for the immune system’s ability to distinguish self from non-self. Specific HLA haplotypes, particularly DR3-DQ2 and DR4-DQ8, confer the highest known risk for developing T1D. JDRF-funded research has been central to identifying these risk haplotypes and understanding how they function at the molecular level. Studies supported by JDRF demonstrated that these HLA variants alter the way antigen-presenting cells display peptides to T cells, effectively setting the stage for an autoimmune attack on the insulin-producing beta cells of the pancreas. Importantly, JDRF also funded research into protective HLA haplotypes, such as DR15-DQ6, which appear to shield carriers from disease even when they are exposed to the same environmental triggers as high-risk individuals. This dual focus on risk and protection has opened the door to novel therapeutic strategies aimed at mimicking the protective effect in susceptible populations.

Beyond HLA: The Expanding Universe of Non-HLA Risk Genes

While the HLA region accounts for roughly 50% of the heritable risk for T1D, the remaining genetic contribution arises from more than 60 non-HLA loci identified to date. JDRF funding was instrumental in the landmark 2007 GWAS that first identified many of these loci, including variants in the insulin gene (INS), the protein tyrosine phosphatase N22 gene (PTPN22), and the cytotoxic T-lymphocyte-associated protein 4 gene (CTLA4). Each of these genes plays a role in immune regulation, and their variants subtly alter the balance between tolerance and autoimmunity. Subsequent JDRF-supported meta-analyses, combining data from multiple GWAS involving tens of thousands of participants, refined these associations and identified additional loci such as IL2RA, IFIH1, and CLEC16A. These discoveries have provided researchers with a comprehensive map of the genetic pathways that drive T1D. That map, in turn, has guided the development of targeted immunotherapies that intervene at specific checkpoints in the autoimmune cascade.

The Genetics of Autoantibody Production

A particularly fertile area of JDRF-funded research concerns the relationship between genetics and the appearance of autoantibodies, which are the earliest detectable markers of T1D. Longitudinal studies, many supported by JDRF, have shown that children with high-risk HLA genotypes begin producing autoantibodies to insulin, GAD65, IA-2, or ZnT8 months or even years before clinical symptoms emerge. JDRF helped establish the Environmental Determinants of Diabetes in the Young (TEDDY) study, a multinational effort that enrolled infants with high-risk genetic profiles and followed them from birth through childhood. TEDDY, partially funded by JDRF, has provided an unprecedented window into the earliest stages of disease development. It has shown that the appearance of a second autoantibody in a child with a single autoantibody is strongly predicted by specific genetic variants, especially in the INS and PTPN22 genes. These insights are now being used to design clinical trials that intervene at the first sign of autoimmunity, before significant beta cell destruction occurs.

JDRF Funding and the Revolution in Genomic Technologies

Genetic research does not happen in a vacuum. It depends on a continuous pipeline of technological innovation that allows scientists to ask increasingly precise questions. JDRF has been a major funder of the technological infrastructure that makes modern T1D genetics possible. The foundation provided early funding for the development of T1D-specific genotyping arrays, which allowed researchers to screen thousands of genetic variants simultaneously at a fraction of the cost of whole-genome sequencing. More recently, JDRF has invested in single-cell RNA sequencing technologies that enable researchers to examine gene expression in individual beta cells, revealing the molecular signatures of vulnerability and resilience at the cellular level. The foundation has also funded efforts to apply long-read sequencing technologies to the HLA region, which is notoriously difficult to analyze with standard short-read methods. These technologies have uncovered structural variants and regulatory elements that were previously invisible, adding new layers of complexity to our understanding of how HLA genes contribute to T1D risk.

From Genetic Discovery to Clinical Application: The Translational Pipeline

Genetic Screening and Primary Prevention Trials

One of the most direct clinical benefits of JDRF-funded genetic research is the ability to identify individuals at the highest risk of developing T1D before the disease process begins. Screening programs such as TrialNet, which JDRF helped establish and continues to fund, use a combination of HLA genotyping and autoantibody testing to identify at-risk relatives of people with T1D. More recently, JDRF has supported population-level screening initiatives that do not require a family history. In Germany, the Fr1da study screened more than 100,000 children aged 2 to 5 years for islet autoantibodies and found that early detection significantly reduced rates of diabetic ketoacidosis at diagnosis. JDRF is now funding efforts to expand similar programs to other countries, including the United States and the United Kingdom. The goal is to create a global infrastructure for early detection that can serve as a platform for prevention trials. The landmark approval of teplizumab in 2022 as the first drug to delay the onset of clinical T1D was built directly on this foundation. Teplizumab was tested in individuals identified through genetic and autoantibody screening programs that JDRF had funded for decades.

Personalized Treatment Strategies Based on Genetic Profile

The era of one-size-fits-all treatment for T1D is coming to an end, and JDRF-funded genetics research is driving the transition. Studies have shown that genetic variants influence not only disease susceptibility but also the rate of beta cell decline after diagnosis. For example, individuals with certain alleles of the INS gene tend to retain more residual insulin production in the first two years after diagnosis, while those with specific PTPN22 variants experience more rapid loss of beta cell function. These genetic markers are now being integrated into clinical trial designs to stratify participants according to their likely trajectory. JDRF is funding efforts to develop polygenic risk scores for T1D that can predict, with increasing accuracy, how rapidly a newly diagnosed patient will progress toward complete insulin dependence. Such scores could help clinicians decide when to initiate intensive insulin therapy or immunomodulatory treatment and could also identify patients who are most likely to benefit from emerging therapies such as beta cell encapsulation or regenerative medicine approaches.

Challenges in T1D Genetic Research: Funding Gaps and Scientific Hurdles

For all the progress made, significant challenges remain. The genetic architecture of T1D is more complex than early studies suggested. Many of the non-HLA risk variants confer only modest increases in risk, making it difficult to use them for prediction at the individual level. The interplay between genetics and environment, which JDRF has funded through studies like TEDDY, remains only partially understood. We know that viral infections, dietary factors such as early introduction of cereals, and the gut microbiome all play a role, but the specific gene-by-environment interactions that trigger disease onset in a genetically susceptible individual are still being identified. Funding gaps also threaten progress. While JDRF has consistently prioritized genetics, the overall research budget for T1D is modest compared to the burden of the disease. Federal funding through the National Institutes of Health has been subject to political uncertainties, and private investment in T1D genetics has been limited compared to more commercially attractive areas such as cancer genomics. JDRF has stepped into this gap, but the foundation cannot do it alone. Sustained, predictable funding is essential for the large-scale longitudinal studies and clinical trials that genetic discovery requires.

Collaborative Networks: How JDRF Catalyzes Global Genetic Research

JDRF’s impact on T1D genetics is not solely a matter of money. The foundation has also been a master builder of collaborative networks that bring together researchers from different disciplines and countries. The JDRF Center for the Biology of Type 1 Diabetes, established in 2023, is a virtual network of laboratories that share data, reagents, and protocols to accelerate discovery. The JDRF-supported T1D Genetics Consortium includes investigators from Europe, North America, and Asia who meet regularly to coordinate large-scale genotyping efforts and meta-analyses. JDRF also played a founding role in the Type 1 Diabetes Genetics Consortium (T1DGC), a global collaboration that collected DNA and clinical data from more than 16,000 individuals from families with multiple affected members. The T1DGC dataset, which JDRF helped fund for more than a decade, remains one of the most widely used resources in T1D genetic research and has been cited in thousands of peer-reviewed publications. By fostering an ethos of open data sharing and precompetitive collaboration, JDRF has made the whole field more efficient and productive than any single institution could be.

The Economic Case for Genetic Research Funding

Investing in T1D genetic research is not only scientifically sound but economically prudent. The annual cost of T1D care in the United States exceeds $14 billion, driven by insulin, continuous glucose monitors, pump supplies, and the treatment of complications. A 2017 analysis commissioned by JDRF found that a cure for T1D would save the U.S. healthcare system more than $33 billion over 10 years, even accounting for the cost of the curative intervention. Genetic research is a necessary precursor to a cure. Without a detailed understanding of the genetic mechanisms that trigger and sustain autoimmunity, efforts to interrupt the disease process will remain blind. JDRF’s strategic decision to fund genetics has generated an extraordinary return on investment. The genetic discoveries funded by JDRF have directly enabled clinical trials of antigen-specific immunotherapy, tolerogenic vaccines, and gene-edited beta cells. Each trial brings us closer to an intervention that could free millions of people from the burden of daily disease management. The economic argument for continued funding is overwhelming.

Future Directions: Gene Editing, Stem Cells, and Next-Generation Genetics

The future of T1D genetic research, heavily supported by JDRF, lies at the intersection of genomics and cellular engineering. CRISPR-Cas9 and other gene-editing tools now make it possible to modify the genomes of stem cells derived from people with T1D, create models of the disease in a dish, and test potential therapies with unprecedented precision. JDRF has funded projects that use gene editing to correct T1D-associated mutations in induced pluripotent stem cells, then differentiate those cells into functional beta cells for transplantation. Other JDRF-supported work aims to use gene editing to modify immune cells so that they are less likely to attack beta cells, creating a kind of “shielded” islet that could be transplanted without immunosuppression. These approaches are not science fiction; they are being funded and tested now, in laboratories supported by JDRF. The foundation has also invested in epigenomics and transcriptomics, recognizing that the genome is not a static blueprint but a dynamic system that responds to environmental signals. Understanding how environmental factors such as viral infections and diet modify the epigenome in genetically susceptible individuals could reveal new targets for prevention.

Patient and Community Engagement: The Human Impact of Genetic Research

The ultimate beneficiaries of JDRF-funded genetic research are people living with T1D and their families. JDRF has been exemplary in involving the patient community in research prioritization. The foundation’s research summits regularly include patient advocates who help set research agendas and ensure that the questions being asked are the ones that matter most to families. Genetic research raises complex questions about risk disclosure, privacy, and psychological impact. JDRF has funded studies on how families respond to learning that a child carries high-risk HLA genotypes and has developed guidelines for the ethical return of genetic results in research settings. The foundation has also worked with advocacy groups to ensure that genetic screening programs are equitable and accessible, particularly to underserved communities that have historically been underrepresented in genomic research. This commitment to ethical practice and community engagement ensures that the benefits of genetic discovery are shared broadly and responsibly.

Conclusion: JDRF Funding as a Catalyst for a Future Without T1D

The story of T1D genetic research over the past 25 years cannot be told without JDRF at its center. From the identification of HLA risk haplotypes to the discovery of dozens of non-HLA risk genes, from the establishment of global consortia to the funding of clinical trials that delay disease onset, JDRF has been the engine that drives discovery forward. The foundation’s funding has not been passive; it has been strategic, adaptive, and relentlessly focused on the goal of a world without T1D. The genetic architecture of this disease is complex, and the scientific challenges remain significant. But the trajectory is clear. With continued investment in genetic research, the dream of personalized prevention, early intervention, and ultimately a cure moves closer to reality. JDRF’s commitment to genetics has brought us to a historic inflection point where the tools we have built can now be applied to end the disease that the foundation was created to fight. The path forward is illuminated by the discoveries JDRF has already made possible. The next breakthroughs depend on sustaining and expanding that funding commitment. For the millions of people living with T1D and the generations not yet born, that investment is not optional. It is essential.